Business
VVT Med Announces Acceptance of Procedure Fee for ScleroSafe® in South Korea
VVT Med Inc. ("VVT Med" or the "Company"), a developer of innovative minimally invasive solutions for the treatment of venous disease, is pleased to announce that a procedure fee has been accepted in South Korea for treatments performed with ScleroSafe®, marking a significant milestone toward commercial market penetration.
About this update from Vvt Med Inc.
[{"type":"text","content":"VANCOUVER, BC, Jan. 13, 2026 /CNW/ - VVT Med Inc. ("VVT Med" or the "Company"), a developer of innovative minimally invasive solutions for the treatment of venous disease, is pleased to announce that a procedure fee has been accepted in South Korea for treatments performed with ScleroSafe®, marking a significant milestone toward commercial market penetration.","length":386,"tagName":"p"},{"type":"text","content":"In South Korea, acceptance of a procedure fee is a critical step that typically follows regulatory approval and reflects clinical validation and professional consensus. Completion of this process enables approved procedures to be performed under an established procedural framework within the national healthcare system.","length":320,"tagName":"p"},{"type":"text","content":"This achievement follows a multi-year, structured market-entry process in South Korea. VVT Med executed a distribution agreement in South Korea in 2022, establishing a local commercial framework for the technology. In 2024, ScleroSafe received regulatory approval from the Korean Ministry of Food and Drug Safety ("MFDS"), enabling its clinical use in the country. In 2025, the Korean Phlebology Society issued a supportive opinion letter highlighting ScleroSafe's clinical and economic value. Following these regulatory and professional milestones, the procedure fee was accepted in December, 2025, allowing physicians to integrate the treatment into routine clinical practice.","length":692,"tagName":"p"},{"type":"text","content":"Supporting these regulatory and clinical milestones is an already-secured distribution agreement (the "Distribution Agreement") in South Korea valued at approximately CAD 2.6 million, reflecting strong local confidence in the technology and enabling a structured commercial rollout.","length":292,"tagName":"p"},{"type":"text","content":""With the distribution framework in place since 2022, MFDS approval achieved in 2024, and now acceptance of a procedure fee, we have completed the key building blocks required for meaningful market entry," said Erez Tetro, CEO of VVT Med. "South Korea is a highly sophisticated medical market, and this milestone positions ScleroSafe for scalable clinical adoption."","length":386,"tagName":"p"},{"type":"text","content":"With these ele...